Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.

Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, Wallace W, Rini BI, Morris-Stiff G, Allende DS, Hamilton T, Finke JH, Diaz-Montero CM.

Cancer Immunol Res. 2019 Oct;7(10):1687-1699. doi: 10.1158/2326-6066.CIR-18-0578. Epub 2019 Aug 22.

PMID:
31439615
2.

Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.

Kieran MW, Goumnerova L, Manley P, Chi SN, Marcus KJ, Manzanera AG, Polanco MLS, Guzik BW, Aguilar-Cordova E, Diaz-Montero CM, DiPatri AJ, Tomita T, Lulla R, Greenspan L, Aguilar LK, Goldman S.

Neuro Oncol. 2019 Mar 18;21(4):537-546. doi: 10.1093/neuonc/noy202.

PMID:
30883662
3.

Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer.

Pfannenstiel LW, Diaz-Montero CM, Tian YF, Scharpf J, Ko JS, Gastman BR.

Cancer Immunol Res. 2019 Mar;7(3):510-525. doi: 10.1158/2326-6066.CIR-18-0054. Epub 2019 Feb 6.

4.

Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ.

Lin L, Rayman P, Pavicic PG Jr, Tannenbaum C, Hamilton T, Montero A, Ko J, Gastman B, Finke J, Ernstoff M, Diaz-Montero CM.

Cancer Immunol Immunother. 2019 Mar;68(3):395-405. doi: 10.1007/s00262-018-2280-3. Epub 2018 Dec 14.

PMID:
30552459
5.

Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma.

Pfannenstiel LW, McNeilly C, Xiang C, Kang K, Diaz-Montero CM, Yu JS, Gastman BR.

Oncoimmunology. 2018 Oct 11;8(1):e1507669. doi: 10.1080/2162402X.2018.1507669. eCollection 2019.

6.

Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma.

Ko JS, Gastman BR, Conic R, Tellez Diaz Trujillo A, Diaz-Montero CM, Billings SD, Tarhini A, Funchain P, Atanaskova Mesinkovska N.

Am J Dermatopathol. 2019 Mar;41(3):180-187. doi: 10.1097/DAD.0000000000001286.

PMID:
30308543
7.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
8.

Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma.

Zahoor H, Pavicic PG Jr, Przybycin C, Ko J, Stephens L, Radivoyevitch T, Jia X, Diaz-Montero CM, Finke J, Rayman PA, Gilligan TD, Grivas P, Ornstein M, Garcia JA, Rini BI.

Medicine (Baltimore). 2018 Sep;97(37):e12344. doi: 10.1097/MD.0000000000012344.

9.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
10.

Challenges faced when identifying patients for combination immunotherapy.

Ernstoff MS, Gandhi S, Pandey M, Puzanov I, Grivas P, Montero A, Velcheti V, Turk MJ, Diaz-Montero CM, Lewis LD, Morrison C.

Future Oncol. 2017 Aug;13(18):1607-1618. doi: 10.2217/fon-2017-0218. Epub 2017 Aug 24. Review.

PMID:
28835114
11.

Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.

Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J.

Clin Cancer Res. 2017 May 1;23(9):2346-2355. doi: 10.1158/1078-0432.CCR-15-1823. Epub 2016 Oct 31.

12.

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.

Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, Finke JH, Rini BI, Lindner DJ.

Br J Cancer. 2016 Oct 11;115(8):920-928. doi: 10.1038/bjc.2016.263. Epub 2016 Aug 25.

13.

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.

Diaz-Montero CM, Finke J, Montero AJ.

Semin Oncol. 2014 Apr;41(2):174-84. doi: 10.1053/j.seminoncol.2014.02.003. Epub 2014 Feb 14. Review.

14.

Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.

Díaz-Montero CM, Zidan AA, Pallin MF, Anagnostopoulos V, Salem ML, Wieder E, Komanduri K, Montero AJ, Lichtenheld MG.

Immunol Res. 2013 Dec;57(1-3):23-33. doi: 10.1007/s12026-013-8456-1.

PMID:
24218360
15.

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.

Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI.

J Immunol. 2012 Aug 15;189(4):1627-38. doi: 10.4049/jimmunol.1103271. Epub 2012 Jul 13.

16.

The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress.

Diaz-Montero CM, Wang Y, Shao L, Feng W, Zidan AA, Pazoles CJ, Montero AJ, Zhou D.

Free Radic Biol Med. 2012 May 1;52(9):1560-8. doi: 10.1016/j.freeradbiomed.2012.02.007. Epub 2012 Feb 15.

17.

Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S.

J Immunother. 2012 Feb-Mar;35(2):107-15. doi: 10.1097/CJI.0b013e318242169f. Review.

PMID:
22306898
18.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.

Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S.

Breast Cancer Res Treat. 2012 Feb;132(1):215-23. doi: 10.1007/s10549-011-1889-0. Epub 2011 Dec 3.

19.

Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.

Montero AJ, Adams B, Diaz-Montero CM, Glück S.

Expert Rev Clin Pharmacol. 2011 May;4(3):329-34. doi: 10.1586/ecp.11.7. Review.

PMID:
22114779
20.

Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.

Díaz-Montero CM, Naga O, Zidan AA, Salem ML, Pallin M, Parmigiani A, Walker G, Wieder E, Komanduri K, Cole DJ, Montero AJ, Lichtenheld MG.

Am J Cancer Res. 2011 Aug 30;1(7):882-96.

21.

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S.

Blood. 2011 Aug 25;118(8):2254-65. doi: 10.1182/blood-2010-12-325753. Epub 2011 Jul 6.

22.

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK.

J Clin Invest. 2010 May;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

23.

Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

Salem ML, Al-Khami AA, El-Naggar SA, Díaz-Montero CM, Chen Y, Cole DJ.

J Immunol. 2010 Feb 15;184(4):1737-47. doi: 10.4049/jimmunol.0902309. Epub 2010 Jan 18.

24.

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.

Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N.

Ann Oncol. 2009 Oct;20(10):1682-7. doi: 10.1093/annonc/mdp054. Epub 2009 Jun 18.

25.

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

Salem ML, Díaz-Montero CM, Al-Khami AA, El-Naggar SA, Naga O, Montero AJ, Khafagy A, Cole DJ.

J Immunol. 2009 Feb 15;182(4):2030-40. doi: 10.4049/jimmunol.0801829.

26.

The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice.

Salem ML, Diaz-Montero CM, El-Naggar SA, Chen Y, Moussa O, Cole DJ.

Vaccine. 2009 Jan 22;27(4):549-57. doi: 10.1016/j.vaccine.2008.11.013. Epub 2008 Nov 21.

27.

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ.

Cancer Immunol Immunother. 2009 Jan;58(1):49-59. doi: 10.1007/s00262-008-0523-4. Epub 2008 Apr 30.

28.

Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.

Díaz-Montero CM, El Naggar S, Al Khami A, El Naggar R, Montero AJ, Cole DJ, Salem ML.

Cancer Immunol Immunother. 2008 Apr;57(4):563-72. Epub 2007 Aug 28.

29.

Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.

Montero AJ, Díaz-Montero CM, Mao L, Youssef EM, Estecio M, Shen L, Issa JP.

Cancer Biol Ther. 2006 Nov;5(11):1494-501. Epub 2006 Nov 19.

PMID:
17369752
30.

PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation.

Díaz-Montero CM, Wygant JN, McIntyre BW.

Eur J Cancer. 2006 Jul;42(10):1491-500. Epub 2006 Jun 8.

PMID:
16759849
32.

Acquisition of anoikis resistance in human osteosarcoma cells.

Díaz-Montero CM, McIntyre BW.

Eur J Cancer. 2003 Nov;39(16):2395-402.

PMID:
14556933
33.

Identification of CD8 T-lymphocyte epitopes in OmpB of Rickettsia conorii.

Li Z, Díaz-Montero CM, Valbuena G, Yu XJ, Olano JP, Feng HM, Walker DH.

Infect Immun. 2003 Jul;71(7):3920-6.

34.

Langerhans cell histiocytosis of the female genital tract: a literature review.

Montero AJ, Díaz-Montero CM, Malpica A, Ramirez PT, Kavanagh JJ.

Int J Gynecol Cancer. 2003 May-Jun;13(3):381-8. Review.

PMID:
12801274
35.

Alpha 4 integrin increases anoikis of human osteosarcoma cells.

Marco RA, Díaz-Montero CM, Wygant JN, Kleinerman ES, McIntyre BW.

J Cell Biochem. 2003 Apr 1;88(5):1038-47.

PMID:
12616540
36.

Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis.

Crocquet-Valdes PA, Díaz-Montero CM, Feng HM, Li H, Barrett AD, Walker DH.

Vaccine. 2001 Dec 12;20(5-6):979-88.

PMID:
11738766
37.

Identification of protective components of two major outer membrane proteins of spotted fever group Rickettsiae.

Díaz-Montero CM, Feng HM, Crocquet-Valdes PA, Walker DH.

Am J Trop Med Hyg. 2001 Oct;65(4):371-8.

PMID:
11693887

Supplemental Content

Loading ...
Support Center